2020 Fiscal Year Final Research Report

Development of bone adhesive treatment with functionally modified platelets

Research Project

PDF

Project/Area Number	19K22675
Research Category	Grant-in-Aid for Challenging Research (Exploratory)
Allocation Type	Multi-year Fund
Review Section	Medium-sized Section 56:Surgery related to the biological and sensory functions and related fields
Research Institution	Chiba University
Principal Investigator	Eto Koji 千葉大学, 大学院医学研究院, 教授 (50286986)
Co-Investigator(Kenkyū-buntansha)	大鳥精司千葉大学, 大学院医学研究院, 教授 (40361430) 折田純久千葉大学, 大学院医学研究院, 特任准教授 (60638310) 志賀康浩千葉大学, 大学院医学研究院, 特任准教授 (90568669) 曽根正光千葉大学, 大学院医学研究院, 特任助教 (90599771)
Project Period (FY)	2019-06-28 – 2021-03-31
Keywords	人工血小板 / iPS細胞 / 骨癒合
Outline of Final Research Achievements	Platelet Rich Plasma (PRP) administration treatment is known to accelerate repairment of bone fracture by bone adhesion machinery. However, stable supply of autologous PRP, along with the diversity of individual PRP quality, never allow the given action in real clinical setting. Our research program confirmed that iPSC-derived megakaryocytes and platelets, whereby we already established mass production methods and stability, contain several growth factors for bone adhesion, resulting in significantly improved bone adhesion in a rat lumbar bone graft model, compared to that by PRP. Moreover, we transduced lentiviral vectors harboring multiple growth factors for tissue repair by iPSC-derived megakaryocytes, which also successfully produced functionally modified platelets.
Free Research Field	再生医学
Academic Significance and Societal Importance of the Research Achievements	脊椎固定術は、難治性複雑骨折や腰椎変性疾患に対して行われ、早期のADL（日常生活動作）回復に寄与するための迅速な骨癒合の実現が必須である。iPS細胞由来血小板製剤の大量製造技術を応用し、均一性の担保された大量生産可能な血小板製剤の骨癒合への応用が確認されたことから、高齢者や外傷患者などのPRPの安定調達が困難な症例に有効と期待できる。さらに遺伝子改変した巨核球細胞株をいわば生産工場、人工血小板をキャリアとして生理活性物質を患部に輸送するための新たなドラッグデリバリーシステムが確立できた。